Synthetic direct and indirect factor Xa inhibitors

Thrombosis Research

Volumn 106, Issue 3, 2002, Pages

  Samama, Meyer Michel ^a  

^a HÔTEL DIEU   (France)

Author keywords

Antithrombotic; DX 9065A; Factor Xa inhibition; Pentasaccharide; Unfractionated heparin

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; PENTASACCHARIDE; TISSUE FACTOR PATHWAY INHIBITOR; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 10A;

BLOOD CLOTTING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; PROTEIN TARGETING; PROTHROMBIN TIME; REVIEW; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VEIN THROMBOSIS; DRUG ANTAGONISM; SYNTHESIS;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; CLINICAL TRIALS; FACTOR XA; HUMANS;

EID: 0036588776     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00080-4     Document Type: Article

References (46)

1. Hemker H.C., Beguin S., Bendetowicz A.V., Wielders S. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Haemostasis. 21:1991;258-272.
2. Ofosu F.A., Fernandez F., Anvari N., Caranobe C., Dol F., Cadroy Y., Petitou M., Mardiguian J., Sie P., Boneu B. Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits. Thromb. Haemost. 60:1988;188.
3. Ofosu F.A., Hirsh J., Esmon C.T., Modi G.J., Smith L.M., Anvari N., Buchanan M.R., Fenton J., Blajchman M.A. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem. J. 257:1989;143-150.
4. Samama M.M., Walenga J.M., Kaiser B., Fareed J. Specific factor Xa inhibitors. Cardiovascular thrombosis. Verstraete M., Fuster V., Topol E.J. Thrombocardiology and Thromboneurology. 1998;Lipincott-Raven Press, Philadelphia.
5. Katakura S., Nagahara T., Hara T., Iwamoto M. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. Biochem. Biophys. Res. Commun. 197:1993;965-972.
6. Beguin S., Choay J., Hemker H.C. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost. 61:1989;379-401.
7. Herault J.P., Bernat A., Pflieger A.M., Lormeau J.C., Herbert J.M. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J. Pharmacol. Exp. Ther. 283:1997;16-22.
8. Eisenberg P.R., Siegel J.E., Abendischein D.R., Miletich J.P. Importance of factor Xa in determining the procoagulant activity of whole blood clots. J. Clin. Invest. 91:1993;1877-1883.
9. Taniuchi Y., Sakai Y., Hisamichi N., Kayama M., Mano Y., Sato K., Hirayama F., Koshio H., Matsumoto Y., Kawasaki T. Biochemical and pharmacological characterization of YM-60828, a newly synthetized and orally active inhibitor of human factor Xa. Thromb. Haemost. 79:1998;543-548.
10. Kawasaki T., Sato K., Sakai Y., Hirayama F., Koshio H., Taniuchi Y., Matsumoto Y. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb. Haemost. 79:1998;410-416.
11. Hara T., Yokoyama A., Morishima Y., Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb. Res. 80:1995;99-104.
12. Yamashita T., Tsuji T., Matsuoka A., Giddings J.C., Yamamoto J. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-He laser-induced thrombosis in rat mesenteric vessel. Thromb. Res. 85:1997;45-51.
13. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama F., Koshio H., Ichilara M., Matsumoto Y. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs. Eur. J. Pharmacol. 350:1998;87-91.
14. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74:1995;635-639.
15. Yokoyama T., Kelly A.B., Marzec U.M., Hanson S.R., Kunitada S., Harker L.A. Antithrombotic effects of orally active synthetic antagonists of activated factor X in non-human primates. Circulation. 92:1995;485-491.
16. Ragosta M., Gimple L.W., Gertzet al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 89:1994;1262-1271.
17. Schwartz R.S., Holder D.J., Holmes D.R. Jr.et al. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor. Results in a porcine model. Circulation. 93:1996;1542-1548.
18. Depasse F., Caplain H., Kunitada S., Samama M.M. Assessment of the pharmacodynamic profile of DX9065a, a direct factor Xa inhibitor, in 36 healthy male subjects: A first study using subcutaneous route. Thromb Haemost, XVIII ISTH Congress, Paris; 2001 (abstract).
19. Leamy A.W., Luettgen J.M., Wong P.C., et al. Pharmacokinetics and antithrombotic efficacy of the selective factor Xa inhibitor DPC 423 in dogs. Thromb Haemost, XVIII ISTH Congress, Paris; 2001 (abstract).
20. Wong P.C., Crain E.J., Watson C.A., Bai S.A., Pruitt J.R., Galemmo R.A., Wexler R.R., Knabb R.M. Antithrombotic effects of DPC602, a potent and selective nonpeptide factor Xa inhibitor, in rabbit models of thrombosis. Thromb Haemost, XVIII ISTH Congress, Paris; 2001 (abstract).
21. Walenga J.M., Peske W.P., Bara L., Samama M.M., Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide. Thromb. Res. 86:1997;1-36.
22. Elalamy I., Lecrubier C., Potevin F., Abdelouahed M., Bara L., Marie J.P., Samama M. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb. Haemost. 74:1995;1384-1385.
23. Walenga J.M., Koza M.J., Lewis B.E.et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thromb. Hemost. 2(Suppl. 1):1996;S21.
24. Amiral J., Lormeau J.C., Marfaing-Koka A., Vissac A.M., Boyer-Neumann C., Tardy B., Herbert M., Meyer D. Absence of cross-reactivity of SR 90107A/ORG 31540 pentasaccharide with antibodies to heparin-PF4 complexes developed on heparin-induced thrombocytopenia. Blood Coagul. Fibrinolysis. 8:1997;114-117.
25. Petitou M., Herbert J.M. Les anticoagulants de synthèse. Pour La Science. 274:2000;28-34.
26. Herbert J.M., Petitou M., Lormeau J.C., Cariou R., Necciari J., Magnani H.N., Zanderberg P., van Amsterdam R.G.M., van Boeckel C.A.A., Meuleman D.G. SR 90107/ORG31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc. Drug Rev. 15:1997;1-26.
27. Boneu B., Necciari J., Cariou R., Sié P., Gabaig Am., Kieffer G., Dickinson J., Lamond G., Moelker H., Mant T., Magmani H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb. Haemost. 74:1995;1468-1473.
28. Herbert J.M., Herault J.P., Bernat A.et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pensaccharide. Blood. 91:1998;4197.
29. Herbert J.M., Hérault J.P., Bernat A., Savi P., Schaeffer P., Driguez P.A., Duchaussoy P.H., Petitou M. SR123781A, a synthetic heparin mimetic. Thromb. Haemost. 85:2001;852-860.
30. Walenga J.M., Bara L., Petitou M., Samama M.M., Fareed J., Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb. Res. 51:1988;23-33.
31. Lormeau J.C., Hérault J.P. The effect of the synthetic pentasaccharide SR 90107/ORG31540 on thrombin generation ex vivo is uniquely due to AT III-mediated neutralization of factor Xa. Thromb. Haemost. 74:1995;1474-1477.
32. Gerotziafas G.T., Bara L., Bloch M.F., Makris P.E., Samama M.M. Comparative effects of synthetic pentasaccharide low molecular weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Blood Coagul. Fibrinolysis. 9:1998;571-580.
33. Walenga J.M., Petitou M., Lormeau J.C., Samama M., Fareed J., Choay J. Antithrombotic activity of a synthetic heparin pentasacccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. 46:1987;187-198.
34. Carrié D., Caranobe C., Saivin S., Houin G., Petitou M., Lormeau J.C., van Boeckel C., Meuleman D., Boneu B. Pharmacokinetic and antithrombotic properties of two pentasacharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood. 84:1994;2571-2577.
35. Vogel G.M.T., van Amsterdam R.G.M., Kop W.J., Meuleman D.G. Pentasaccharide and Orgaran® arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb. Haemost. 69:1993;29-34.
36. Cadroy Y., Hanson S.R., Harker L.A. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb. Haemost. 70:1993;631-635.
37. Bernat A., Hoffmann P., Sainte-Marie M., Herbert J.M. The synthetic pentasaccharide SR 90107A/Org 31540 enhances tissue-type plasmainogen activator-induced thrombolysis in rabbits. Fibrinolysis. 10:1996;191-197.
38. Turpie A.G.G., Gallus A.S., Hoek J.A. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med. 344:2001;619-625.
39. The Rembrandt Investigators Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation. 102:2000.
40. Coussement P.K.et al. for the PENTALYSE investigators A synthetic factor Xa inhibitor (SR90107/ORG31540) as an adjunct to fibrinolyse in acute myocardial infarction. The PENTALYSE study. Eur. Heart J. 22:2001;1716-1724.
41. Vuilleminot A., Schiele F., Meneveau N., Claudel S., Donat F., Fontecave S., Cariou R., Samama M.M., Bassand J.P. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as a antithrombotic agent. A pilot study in the setting of coronary angioplasty. Thromb. Haemost. 81:1999;214-220.
42. Lassen M.R., Bauer K.A., Eriksson B.I., Turpie A.G. European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 359:2002;1715-1720.
43. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. The PENTATHLON 2000 Study Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 359:2002;1721-1726.
44. Bauer K.A.et al. for the Steering Committee of the Pentasaccharide in major knee surgery group Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345:2001;1305-1310.
45. Eriksson B.I.et al. for the Steering Committee of the Pentasaccharide in hip-fracture surgery group Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345:2001;1298-1304.
46. Walenga J.M., Jeske P.W., Hoppensteadt D., Kaiser B. Factor Xa inhibitors today and beyond current opinion in cardiovascular pulmonary and renal investigation. Drugs. 1:1999;13-27.